---
title: "nccn_flowchart_of_mantle_cell_lymphoma"
date: "2024-09-25"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[mantle cell lymphoma]]

# nccn_flowchart_of_mantle_cell_lymphoma

[[workup_of_mantle_cell_lymphoma.md|workup of mantle cell lymphoma]]

## Aggressive induction therapy

> Preferred regimens (in alphabetical order)

- [[lyma_regimen.md|LyMA regimen]]: RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) x 4 cycles
  followed by RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for non-PET CR
- NORDIC regimen: Dose-intensified induction immunochemotherapy with rituximab + cyclophosphamide, vincristine,
  doxorubicin, prednisone (maxi-CHOP) alternating with rituximab + high-dose cytarabine
- Rituximab, bendamustinec followed by rituximab, high-dose cytarabinee
- [[triangle_regimen.md|TRIANGLE regimen]]: Alternating RCHOP + covalent BTKig/RDHA (rituximab, dexamethasone, cytarabine) + platinum
  (carboplatin, cisplatin, or oxaliplatin) (category 2A for ibrutinib; category 2B for acalabrutinibj or zanubrutinib)
- HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and
  cytarabine) + rituximabd (NOTE: There are conflicting data regarding the need for consolidation with HDT/ASCR) â€¢ RBAC500 (rituximab, bendamustine,c cytarabine)

## Less aggressive induction therapy

- Bendamustine + rituximab
- VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone) â€¢ RCHOPf
- Lenalidomide (continuous) + rituximab
  Other recommended regimen
- Acalabrutinibg,j (continuous) + rituximab

## MAINTENANCE AFTER HDT/ASCR OR AGGRESSIVE INDUCTION THERAPY

- Covalent BTKig x 2 yearsh (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib) + rituximab every 8 weeks x 3 years

## MAINTENANCE AFTER LESS AGGRESSIVE INDUCTION THERAPY

Rituximab every 8 weeks for 2â€“3 years following RCHOP (category 1) or Bendamustine + rituximab Maintenance rituximab following VR-CAP or RBAC500 has not been evaluated
